A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

NCT04288089 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Receptors, Estrogen
Genes, Erbb-2
Breast Neoplasms

Interventions

DRUG: Palbociclib (75, 100, 125 milligram [mg])
DRUG: H3B-6545 (150, 300, 450 mg)

Sponsor

Eisai Inc.